Skip to main content
The power to target muscle to
stop or reverse disease progression
We support all people, families and caregivers living with rare diseases, this Rare Disease Day and every day

Scientific Publications & Presentations

March 3-6, 2024
Initial Data from the DELIVER Trial of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping Presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
March 3-6, 2024
Initial Data from the ACHIEVE Trial of DYNE-101 in Adults with Myotonic Dystrophy Type 1 (DM1) Presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
February 16, 2024
Patient engagement in clinical trial design for rare neuromuscular disorders: impact on the DELIVER and ACHIEVE clinical trials Presented at Parent Project Italy’s XXI International Conference on Duchenne and Becker Muscular Dystrophy
May 17, 2023
The FORCE™ Platform Delivers Oligonucleotides to the Brain in a DM1 Mouse Model and in NHPs Presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
April 22-27, 2023
ACHIEVE Trial, a Randomized, Placebo-Controlled, Multiple Ascending Dose Study of DYNE-101 in Individuals With Myotonic Dystrophy Type 1 (DM1)
Presented at the American Academy of Neurology (AAN) Annual Meeting Oral Presentation Poster
March 19-22, 2023
March 19-22, 2023
March 19-22, 2023
October 11–15, 2022
Building a FORCE platform-based DMD franchise for the treatment of individuals with mutations amenable to exon skipping Presented at the 27th International Hybrid Annual Congress of the World Muscle Society
May 14, 2021